Shares of Alzamend Neuro (ALZN) slid 7.1% to $1.45 on August 24, extending a volatile week after the clinical-stage biotech disclosed a shelf registration allowing selling stockholders to dump up to 98,388,305 shares into the open market. For a company with a micro-cap footprint and no approved products, the sheer scale of potential new supply raises existential questions about shareholder dilution. Alzamend Neuro's 98-Million-Share Filing Threatens to Flood a $7 Million Company — Is There Anything Left for Existing Shareholders?
Shares of Alzamend Neuro (ALZN) tumbled 7.1% to $1.45 on Monday, extending a choppy week after the clinical-stage biotech filed an S-1 registration with the SEC allowing selling stockholders to offload up to 98,388,305 shares into the open market. For a company whose entire market value barely cracks single-digit millions, the scale of the potential stock flood raises serious questions about what existing investors actually own.
• The Numbers Are Staggering Relative to the Company's Size. Alzamend's market capitalization stood at roughly $6.9 million as of mid-August. The 98.4-million-share registration — filed with the SEC on August 21 — dwarfs the company's existing share count of under 5 million publicly traded shares. If fully converted and sold, it would multiply the outstanding shares more than 20-fold, crushing the value of each existing share through dilution — meaning every current stockholder's slice of the pie gets dramatically thinner.
• This Offering Traces Back to a Lifeline Deal With an Affiliate. On August 4, Alzamend disclosed it had entered a Securities Purchase Agreement with Ault Lending for up to $25 million in newly created Series D Convertible Preferred Stock, closing an initial $7.5 million tranche.
Those preferred shares convert into common stock at a variable price — the greater of a $0.2668 floor and 80% of the lowest closing bid over five trading days, capped at $2.00. That formula means the lower the stock sinks, the more shares get created, amplifying dilution in a downward spiral.
• Zero Revenue and Vanishing Cash Make the Dilution Almost Inevitable. Alzamend posted $0 in revenue for fiscal 2026 and a net loss of $8.77 million.
The company held just $711,000 in cash against an $8.1 million annual burn rate, giving it roughly one month of runway.
Management itself acknowledged current cash is insufficient to cover the next 12 months. The Ault deal isn't optional — it's survival funding.
• A Pattern of Massive Dilutive Filings Signals a Structural Problem. In 2024, Alzamend filed to register 125 million shares for a different investor, Orchid Finance, under a similar convertible preferred structure.
Since its 2021 IPO, the company's market cap has collapsed from $1.15 billion to $6.9 million — a 99.4% decline. Each funding round has diluted prior holders into near-oblivion. With no product revenue on the horizon and trials still in early stages, shareholders face continued erosion with no clear catalyst to reverse it.